Vasoactive intestinal peptide (VIP) has potent growth-related actions that influence cell mitosis, neuronal survival, and neurodifferentiation in cell culture. VIP can also produce dramatic growth in postimplantation mouse embryos in vitro, characterized by large increases in cell number. The goal of the present study was to assess the role of VIP on early nervous system development in vivo. Pregnant mice were treated with a specific antagonist to VIP. Prenatal administration of the antagonist early in development (E9-Ell) produced severe microcephaly characterized by decreased embryonic brain weight with reduced DNA and protein content. The retardation of growth was disproportionally manifested in the brain compared with the body and was prevented by co-treatment with VIP. Identical treatment with the antagonist later in gestation had no detectable effect on embryonic growth. VIP receptors, which were restricted to the central nervous system during this stage of embryonic development, were increased in the neuroepithelium of antagonist-treated embryos while the number of cells in S-phase was significantly decreased. Thus, VIP regulates brain growth in vivo and inhibition of its action provides new insight into a molecular mechanism for microcephaly. (J. Clin. Invest. 1994.94
Introduction
Understanding the pathophysiology of microcephaly is not only important for the development of preventive and therapeutic strategies, but also for identification of the essential elements regulating central nervous system (CNS)1 ontogenesis. Although environmental factors have been associated with microcephalies, (1) no etiological factor has been unequivocally identified. Furthermore, information on the ontogenetic events and molecular mechanisms involved in the pathology of CNS growth retardation is sparse. Recent reports have shown that inhibition of insulin-like growth factor-2 activity induced a reduction in brain size. However, insulin-like growth factor-2 blockade produced a proportional reduction in both brain and body, (2) suggesting that microcephaly involves interference with other, more specific, growth factors. The most extensively studied experimental model for microcephaly is based on administration of the alkylating agent, methylazoxymethanol to pregnant rats (3) (4) (5) . Prenatal treatment with this short-acting antimitotic agent produces severe microcephaly and behavioral deficits in newborn rats. Other substances that have been studied as inducers of microcephaly and neuroanatomical deficits include methylnitrosourea (6) and ochratoxin A (7) .
A new model for microcephaly is now proposed based on the inhibition of the mitogenic and/or survival-promoting actions of vasoactive intestinal peptide (VIP) (8) (9) (10) (11) . This study is the first to describe a microcephalic outcome produced by the inhibition of a specific neurochemical: VIP. The growth retardation was produced using a specific VIP antagonist (VA, neurotensin-VIP 7-28 hybrid antagonist) (12) (13) (14) .
This work had its foundation in previous observations indicating that VIP has unique neurotrophic properties as demonstrated in primary cultures from the central nervous system. Subnanomolar amounts of VIP have been shown to increase the survival of spinal cord neurons and blockade of endogenous VIP by specific antiserum or VIP antagonists has produced neuronal cell death (8, 12) . These survival-promoting effects were shown to be mediated by secondary molecules released from glia (9, 15) . Subsequent reports have indicated that VIP can promote mitosis of astroglia (9) and neuroblasts from sympathetic ganglia (11) . These in vitro studies were extended recently to whole embryo cultures (10) . A 4-h treatment with VIP (10-10 M to 10-7 M) was shown to dramatically stimulate growth of embryonic mice at gestational day 9.5 (E 9.5). VIP caused a concentration-dependent increase in somitic number, a marker of growth and maturation. An average of 5.2 new somites were produced with 10-7 M VIP, while control embryos acquired an average of 2.2 new somites during the treatment period. Similar VIP growth-stimulating effects (11-63% of increase from control) were evident on embryonic volume. In comparison to control embryos in culture, VIP increased the DNA and protein content by 103 and 63%, respectively, indicating that VIP induced growth through large increases in mitotic activity and/or in survival of dividing precursors. When cells were labeled in S-phase with bromodeoxyuridine, it became evident that VIP produced a concentration-dependent increase in the number of cells in S-phase (up to a 5-6-fold increase) in both neuronal and nonneural tissues. At this stage, virtually all of the detectable VIP binding sites were confined to the central nervous system (10, 16) and addition of VIP to the culture medium produced a concentration-dependent decrease in binding sites. Addition of VA partially blocked both the VIPstimulated increases in embryonic growth and the VIP-induced down-regulation of VIP binding sites (10) . Together these data suggest that during the period between E9 (closure of neural tube) and E12 (onset of neocortical neuronal migration), VIP regulates embryo growth through VIP binding sites localized to the CNS. At this time, the embryo may be vulnerable to pharmacological blockade of VIP actions that have consequences to brain development. This is also the period in which the production of precursor cells for the whole brain occurs, as does the commitment of cells to the glial lineage (17) . With this critical period as a focus, the purpose of the present work was to assess the role of VIP on early CNS growth by injecting pregnant mice with an antagonist to VIP.
Methods
VA-hybrid VIP antagonist. To assess the role of VIP on early CNS growth a VIP antagonist was used. The pharmacological specificity of the VA has been investigated (12) (13) (14) . VA is a hybrid peptide consisting of a carboxy fragment of VIP (VIP 7-28) and a six-amino acid fragment of neurotensin (13) . This antagonist was found to have no agonist activity and to recognize both high and low affinity VIP binding sites on astroglia (12) . At the lower affinity site associated with the generation of cAMP, VA exhibited 10-fold greater potency than VIP in displacing radiolabeled VIP from cortical astrocytes. At the high affinity site, VIP and VA were equipotent in binding displacement studies. The VIP antagonist exhibited tissue specificity as it did not block VIP receptors on lymphocytes (14) . In contrast, VA inhibited VIP-stimulated proliferation and growth of lung cancer cells (18). Previous studies have shown that VA treatment of CNS cultures produced a 30% loss in the number of neurons (12) . Administration of VA to neonatal animals caused delays in the acquisition of developmental milestones and damage to cerebral cortical neurons (19, 20) . Importantly, co-treatment with neurotensin did not influence the biological activity associated with VA (19 (26) , was incorporated and detected as described (27 (Fig. 1, A Fig. 1 D) . When dams were allowed to deliver, VA-treated pups were born alive at term. A related peptide, secretin, had no effect on the parameters under study (not shown). Co-treatment with a ten-fold molar excess of VIP abolished the VA-induced impairment of CNS and body growth ( Figs. 1 and 2 A) . Co-treatment with the VIPlike peptide, PACAP, did not prevent the impairment of growth produced by VA (Figs. 1 and 2 A) . However, PACAP co-treatment resulted in greater decreases in body DNA, protein, and weight than were produced by VA alone (Fig. 1) . Furthermore, PACAP 6-27, a putative PACAP antagonist (22) , failed to inhibit embryonic growth (Fig. 1) . Treatment of the dams with VIP alone was toxic (0.002 to 0.02 l.sglg) or lethal (0.2 to 2 jg/ g) to the embryos (not shown). Histological and immunocytochemical analyses. Compared with control, VA treatment resulted in a reduction in the thickness of the cortical wall (Fig. 2, B and C) bryos, VA produced a decrease in the number of cells in Sphase (Fig. 3) , affecting predominantly neural (82% of control) rather than non-neural (96% of control) tissues. Co-treatment with VIP but not PACAP, prevented the VA-mediated decrease in the number of BRDU-positive cells (Fig. 3) . Co (Fig. 4) . A lower concentration of VA (0.2 jig/g) did not reveal a significant increase VIP binding sites. The partial PACAP antagonist (PACAP 6-27) had no effect. VIP binding sites were present in the germinal neuroepithelium at E9.8 (Fig. 4) (31) and a similar human (32) form of the VIP receptor recently have been cloned. This receptor was detected in lung, liver and intestine as well as in the cortex, hippocampus, hypothalamus, and cerebellum of the brain. A second, high affinity receptor for VIP has been cloned which was enriched in rat pituitary, olfactory bulb, thalamus, hippocampus, and the suprachiasmatic nucleus (33) . The two VIP receptors were found to be pharmacologically distinct and had a 50% identity at the amino acid level. Similarities were greatest in the putative transmembrane domains. A similarity in transmembrane domains was also found between the two VIP receptors and the PACAP family of receptors, which consists of five receptors derived from the same gene by alternative splicing (34, 35) . These PACAP receptors have different affinities for PACAP 38, PACAP 27, and VIP and in several tissues including lung, liver, and intestines a shared PACAP/VIP receptor has been identified. However, specific high affinity PACAP receptors have been identified in the brain which do not recognize VIP (36) . The failure of PACAP to act like VIP and prevent VA-mediated inhibition of growth and development suggests that PACAP was unable to act at those receptor sites at which VA inhibited growth and development. Previous studies of the mitogenic properties of low concentrations (< 100 pM) of VIP on astroglia suggested that the receptor mediating these events was not linked to adenylate cyclase (9); rather, a calcium mobilizing mechanism was most likely associated with both the secretory and mitogenic actions of VIP (37) . When the expression and signal transduction pathways of the known VIP and PACAP receptors have been characterized in the embryonic CNS, the identity of the growth-related receptor(s) may become apparent.
The previous discussion presumed that VIP was the endogenous ligand that was blocked by administration of the hybrid peptide antagonist. Certainly, the fact that the antagonist has a 80% identity with VIP (amino acids 7-28) supports the conclusion that VIP is the natural ligand for this drug. Furthermore, in vitro studies (12, 14) and in vivo studies (13, 19) have demonstrated specificity. In the current study, co-treatment with a 10-fold molar excess of VIP (and not with VIP-related peptides) abolished the VA-induced impairment of CNS and body growth ( Fig. 1 and 2) , demonstrating the specificity of the observed effects. However, these results could have been achieved if the antagonist was blocking some other VIP-like substance. To address this possibility, a series of experiments were designed to test whether PACAP might play such a role. However, cotreatment of the VIP antagonist with PACAP did not prevent the impairment of growth produced by VA ( Fig. 1 and 2 A) . Furthermore, PACAP 6-27, a partial PACAP antagonist (22) , had no effect on embryonic growth (Fig. 1) , suggesting that VA inhibits a specific VIP function not shared by PACAP. Although co-treatment with PACAP had no effect on the VAinduced reduction of cells in S-phase in the CNS, it resulted in a decrease of BRDU labeling in the body not observed in embryos treated with VA alone (Fig. 3 ). This suggests that PACAP, at this concentration, had an effect on cell number opposite to that reported for VIP. Thus, based on these experiments, the most likely explanation of the data was that the hybrid antagonist was not only specifically blocking the effects of VIP, but also acting at a VIP receptor which was not stimulated/recognized by PACAP.
The radial glial fascicles and their affiliated migrating neurons constitute an ontogenic unit organizing the developing cerebral cortex (38, 39) . The extent of the cortical surface is determined by the number of these adjacent neuronal-glial modules. These units are present in the primitive neuroepithelium soon after neural tube closure, much earlier than the initiation of neuronal migration (17) . In VA-treated animals, the integrity of the neuronal-glial unit was preserved, as demonstrated by the normal glial organization and density and by the conserved cortical plate cytoarchitecture and thickness. In contrast, the cortical surface was reduced, strongly suggesting a diminished number of neuronal-glial modules formed in VA-treated embryos. Three possibilities have been considered: (a) the mitotic inhibition and/or cell death induced by the VA in the primitive germinal zone primarily affected the glial precursors with a secondary inhibition of neuronal production due to lower amounts of neurotrophic factors secreted by glial cells; (b) the reverse may also occur; i.e., the neuronal precursors may be reduced with a secondary effect on glia production; (c) both neuronal and glial populations could be affected by VA.
Treatment with the VIP antagonist resulted in a reduction of the intermediate zone of the cortical wall. This loss might reflect a decreased neuronal migration due to a reduced number of neuronal precursors in the germinative zone.
VIP antagonist treatment of mid-gestation mice resulted in an increase in the number of VIP binding sites observed in the CNS of the embryos. Additionally, in previous studies we showed that VIP treatment decreased VIP binding in both the neonatal (20) and embryonic (10) brain and that VA treatment increased VIP binding (10) . Our explanation of this response was that the VIP antagonist-induced an upregulation of VIP receptors. This increase in VIP binding sites strongly suggests that the antagonist reached CNS receptors in the present study and that the increase was a supersensitivity pharmacological response attributable to chronic blockade of the VIP receptors.
These findings indicate that the effects of the VIP antagonist on embryonic growth were due to actions on VIP receptors in the embryonic CNS. As emphasized previously, the lack of any apparent growth in response to PACAP suggests that those receptors which can be occupied by both VIP and PACAP were probably not involved in VIP-mediated increases in mitogenesis.
The microcephaly produced by the VIP antagonist showed striking age dependency. In contrast to the mitotic inhibitory effects of VA observed at E9.8, the number of S-phase cells in the El1.8 and E17.8 embryos was not significantly changed from that of control (data not shown). In addition, the embryos treated between E12.3-14.8 and E15.3-17.8 did not display growth retardation of either CNS or body. These data suggest that the VIP regulation of cell division was stage specific as it was limited to the developmental period between E9 and Eli, in agreement with previous in vitro results (10) . The transient presence of VIP receptors on germinal neuroepithelium may explain this marked stage dependency to the vulnerability to VA. In addition, the marked developmental sensitivity argues against the VIP antagonist producing indirect effects on the fetus through hemodynamic, ischemic, and/or possible toxic effects on maternal systems. Alternatively, the stage dependency of the VIP antagonist effects on brain growth might be related to a reduced ability of the antagonist to reach the embryonic brain at later stages, making it necessary to use higher doses of VA to elicit changes in older brains. However, radiolabeled VA has been found to reach the brains of E16 to E18 rat fetuses after either intraperitoneal (0.005% reached the fetal brain) or intrauterine (0.01% reached the fetal brain) treatment of the mother (I. Gozes, unpublished results). These data suggest that VA was accessible to the fetal brain of the mouse from El1 to E17, but did not have a growth-inhibiting effect.
The present study has shown that administration of a VIP antagonist to a mid-gestational mouse produced a severe microcephaly in the fetus. This effect is believed to be associated with inhibition of mitosis and/or decreased cell survival of dividing precursors in the primitive neuroepithelium during a critical period in development. This in vivo evidence underscores the importance of VIP in the normal growth and development of the embryo and also furnishes a model for microcephaly. These data imply that any interference, whether pharmacological, viral, or nutritional, with VIP action at this critical period in development may result in reduced brain size. Our hope is that an understanding of VIP action during pregnancy may provide insight into formulating a more unifying hypothesis for microcephaly in children.
